Endocrine Abstracts

Neuroendocrine tumors (NETs) represent the second most common malignancy of the small bowel (SB) and despite their indolent nature, NET liver metastasis (NETLMs) will develop in 50 to 60% of patients. Although there have been recent advances in the therapeutic armamentarium in patients with advanced NETs, surgical resection remains the only potentially curative intervention for patients with NETLMs. However, patients whose liver has been significantly invaded by the tumour (mo...